First-in-Human Study of STX-478, a Mutant Selective PI3K alpha Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor
Details
Age
Adult
Type of Study
Treatment
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Anthony Elias, MD
Study ID
Protocol Number: 23-0200
More information available at ClinicalTrials.gov: NCT05768139
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers